Reteplase
Administration
- Type: Thrombolytic
- Dosage Forms: injection
- Routes of Administration: IV
- Common Trade Names: Retavase
Indications
- Thrombolysis in STEMI
Adult Dosing
- 10 units IVx2
Pediatric Dosing
- Not approved for use in pediatrics
Special Populations
Pregnancy Rating
- Category C
Lactation risk
- Caution advised while breastfeeding
Renal Dosing
- Adult: n/a
Hepatic Dosing
- Adult: n/a
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Intracranial hemorrhage
- Severe bleeding
- Reperfusion arrhythmia
- Hypersensitivity reaction
- Cholesterol embolism
Common
- Bleeding
Pharmacology
- Half-life: 13-16 min
- Metabolism: Liver, kidney
Mechanism of Action
- Binds to fibrin, converts tissue plasminogen to plasmin, promoting thrombolysis[1]
References
- Reteplase [monograph]. Epocrates Version. 20.2 [iPhone]. Epocrates, Inc, San Francisco, CA. Available from https://online.epocrates.com/. Accessed March 26, 2020.
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.